BGMSP Fundamental Analysis - BIO GREEN MED SOLUTION - BGMS 6 PERP

Name: BIO GREEN MED SOLUTION - BGMS 6 PERP (BGMSP) Stock
Brand: BIO GREEN MED SOLUTION - BGMS 6 PERP
Rating: 3.5 (3 reviews)

Fundamental Rating

BGMSP gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 531 industry peers in the Biotechnology industry. The financial health of BGMSP is average, but there are quite some concerns on its profitability. BGMSP is valied quite expensively at the moment, while it does show a decent growth rate.

Quickly go to:

1. Profitability

1.1 Basic Checks

BGMSP had negative earnings in the past year.

In the past year BGMSP has reported a negative cash flow from operations.

In the past 5 years BGMSP always reported negative net income.

BGMSP had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

BGMSP has a worse Return On Assets (-146.13%) than 84.75% of its industry peers.

Looking at the Return On Equity, with a value of -177.11%, BGMSP is doing worse than 65.16% of the companies in the same industry.

		Industry Rank	Sector Rank
ROA	-146.13%
ROE	-177.11%
ROIC	N/A

ROA(3y)-203.37%

ROA(5y)-137.74%

ROE(3y)N/A

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

BGMSP does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

BGMSP does not have a ROIC to compare to the WACC, probably because it is not profitable.

BGMSP has more shares outstanding than it did 1 year ago.

Compared to 5 years ago, BGMSP has more shares outstanding

BGMSP has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

2.2 Solvency

BGMSP has an Altman-Z score of -130.95. This is a bad value and indicates that BGMSP is not financially healthy and even has some risk of bankruptcy.

BGMSP's Altman-Z score of -130.95 is on the low side compared to the rest of the industry. BGMSP is outperformed by 96.42% of its industry peers.

There is no outstanding debt for BGMSP. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Altman-Z	-130.95

ROIC/WACCN/A

WACC8.75%

2.3 Liquidity

A Current Ratio of 5.77 indicates that BGMSP has no problem at all paying its short term obligations.

BGMSP's Current ratio of 5.77 is fine compared to the rest of the industry. BGMSP outperforms 61.96% of its industry peers.

A Quick Ratio of 5.77 indicates that BGMSP has no problem at all paying its short term obligations.

BGMSP has a better Quick ratio (5.77) than 62.15% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	5.77
Quick Ratio	5.77

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

BGMSP shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 96.85%, which is quite impressive.

Looking at the last year, BGMSP shows a very negative growth in Revenue. The Revenue has decreased by -87.50% in the last year.

EPS 1Y (TTM)96.85%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%99.43%

Revenue 1Y (TTM)-87.5%

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%-100%

3.2 Future

BGMSP is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 57.16% yearly.

The Revenue is expected to grow by 1049.89% on average over the next years. This is a very strong growth

EPS Next Y39.49%

EPS Next 2Y19.4%

EPS Next 3Y57.16%

EPS Next 5YN/A

Revenue Next Year88.68%

Revenue Next 2Y37.36%

Revenue Next 3Y1049.89%

Revenue Next 5YN/A

3.3 Evolution

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for BGMSP. In the last year negative earnings were reported.

Also next year BGMSP is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

BGMSP's earnings are expected to grow with 57.16% in the coming years. This may justify a more expensive valuation.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y19.4%

EPS Next 3Y57.16%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

BGMSP has a Yearly Dividend Yield of 7.50%, which is a nice return.

BGMSP's Dividend Yield is rather good when compared to the industry average which is at 90.83. BGMSP pays more dividend than 99.44% of the companies in the same industry.

BGMSP's Dividend Yield is rather good when compared to the S&P500 average which is at 2.36.

		Industry Rank	Sector Rank
Dividend Yield	7.5%

5.2 History

The dividend of BGMSP decreases each year by -37.21%.

BGMSP has been paying a dividend for over 5 years, so it has already some track record.

Dividend Growth(5Y)-37.21%

Div Incr YearsN/A

Div Non Decr YearsN/A

5.3 Sustainability

DPN/A

EPS Next 2Y19.4%

EPS Next 3Y57.16%

More info and screens

Find the best dividend stocks

Show peers with best dividend

BIO GREEN MED SOLUTION - BGMS 6 PERP

NASDAQ:BGMSP (11/14/2025, 8:00:01 PM)

5.22

-0.78 (-13%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)11-10 2025-11-10

Earnings (Next)03-31 2026-03-31/amc

Inst Owners1.06%

Inst Owner ChangeN/A

Ins Owners63.57%

Ins Owner ChangeN/A

Market Cap18.27M

Revenue(TTM)10.00K

Net Income(TTM)-6.43M

Analysts43.33

Price TargetN/A

Short Float %0.02%

Short Ratio0.14

Dividend

		Industry Rank	Sector Rank
Dividend Yield	7.5%

Yearly Dividend0.03

Dividend Growth(5Y)-37.21%

DPN/A

Div Incr YearsN/A

Div Non Decr YearsN/A

Ex-Date10-20 2025-10-20 (0.15)

Surprises & Revisions

EPS beat(2)N/A

Avg EPS beat(2)N/A

Min EPS beat(2)N/A

Max EPS beat(2)N/A

EPS beat(4)N/A

Avg EPS beat(4)N/A

Min EPS beat(4)N/A

Max EPS beat(4)N/A

EPS beat(8)N/A

Avg EPS beat(8)N/A

EPS beat(12)N/A

Avg EPS beat(12)N/A

EPS beat(16)N/A

Avg EPS beat(16)N/A

Revenue beat(2)0

Avg Revenue beat(2)-100%

Min Revenue beat(2)-100%

Max Revenue beat(2)-100%

Revenue beat(4)1

Avg Revenue beat(4)-50.98%

Min Revenue beat(4)-100%

Max Revenue beat(4)96.08%

Revenue beat(8)N/A

Avg Revenue beat(8)N/A

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)N/A

PT rev (3m)N/A

EPS NQ rev (1m)0%

EPS NQ rev (3m)N/A

EPS NY rev (1m)0%

EPS NY rev (3m)N/A

Revenue NQ rev (1m)0%

Revenue NQ rev (3m)N/A

Revenue NY rev (1m)0%

Revenue NY rev (3m)N/A

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S	1827
P/FCF	N/A
P/OCF	N/A
P/B	5.03
P/tB	5.03
EV/EBITDA	N/A

EPS(TTM)-122.08

EYN/A

EPS(NY)-1.14

Fwd EYN/A

FCF(TTM)-2.49

FCFYN/A

OCF(TTM)-2.49

OCFYN/A

SpS0

BVpS1.04

TBVpS1.04

PEG (NY)N/A

PEG (5Y)N/A

Graham NumberN/A

Profitability

		Industry Rank	Sector Rank
ROA	-146.13%
ROE	-177.11%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	N/A
FCFM	N/A

ROA(3y)-203.37%

ROA(5y)-137.74%

ROE(3y)N/A

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexgc growth 3YN/A

ROICexgc growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

F-Score3

Asset Turnover0

Health

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Debt/EBITDA	N/A
Cap/Depr	N/A
Cap/Sales	N/A
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	5.77
Quick Ratio	5.77
Altman-Z	-130.95

F-Score3

WACC8.75%

ROIC/WACCN/A

Cap/Depr(3y)N/A

Cap/Depr(5y)N/A

Cap/Sales(3y)N/A

Cap/Sales(5y)N/A

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)96.85%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%99.43%

EPS Next Y39.49%

EPS Next 2Y19.4%

EPS Next 3Y57.16%

EPS Next 5YN/A

Revenue 1Y (TTM)-87.5%

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%-100%

Revenue Next Year88.68%

Revenue Next 2Y37.36%

Revenue Next 3Y1049.89%

Revenue Next 5YN/A

EBIT growth 1Y48.71%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next YearN/A

EBIT Next 3YN/A

EBIT Next 5YN/A

FCF growth 1Y57.07%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y57.05%

OCF growth 3YN/A

OCF growth 5YN/A

BIO GREEN MED SOLUTION - BGMS 6 PERP / BGMSP FAQ

What is the fundamental rating for BGMSP stock?

ChartMill assigns a fundamental rating of 3 / 10 to BGMSP.

What is the valuation status for BGMSP stock?

ChartMill assigns a valuation rating of 1 / 10 to BIO GREEN MED SOLUTION - BGMS 6 PERP (BGMSP). This can be considered as Overvalued.

What is the profitability of BGMSP stock?

BIO GREEN MED SOLUTION - BGMS 6 PERP (BGMSP) has a profitability rating of 0 / 10.

Can you provide the expected EPS growth for BGMSP stock?

The Earnings per Share (EPS) of BIO GREEN MED SOLUTION - BGMS 6 PERP (BGMSP) is expected to grow by 39.49% in the next year.

BIO GREEN MED SOLUTION - BGMS 6 PERP (BGMSP) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

5.2 History

5.3 Sustainability

More info and screens

BIO GREEN MED SOLUTION - BGMS 6 PERP / BGMSP FAQ

What is the fundamental rating for BGMSP stock?

What is the valuation status for BGMSP stock?

What is the profitability of BGMSP stock?

Can you provide the expected EPS growth for BGMSP stock?